$RGRX News
Last published 3y ago
- 3y agoRGRXFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259PR NewswireROCKVILLE, Md., April 13, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and
- 3y agoRGRXRegeneRx Issues Letter To StockholdersPR NewswireROCKVILLE, Md., April 11, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair,
- 3y agoRGRXThymosin Beta 4 Research Leads Toward Potential Future Anti-aging TherapyPR NewswireROCKVILLE, Md., Jan. 31, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and
- 3y agoRGRXPublication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic KeratopathyPR NewswireROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and
- 4y agoRGRXRegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye DiseasePR NewswireExpect ARISE-4 Trial to Begin Around 2nd Quarter of 2023 ROCKVILLE, Md., Oct. 24, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug
- 4y agoRGRXRegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)PR NewswireFirst of Two Phase 3 NK Trials Expected to Start in November 2022 ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue prote
- 4y agoRGRXRegeneRx Issues 2022 Letter To StockholdersPR NewswireUpdate on Product Candidates, FDA Regulatory Strategy, Operations ROCKVILLE, Md., Aug. 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue pr
- 4y agoRGRXRegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic KeratitisPR NewswireROCKVILLE, Md., July 18, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. jo
- 4y agoRGRXRegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259PR NewswireROCKVILLE, Md., June 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. joi
- 4y agoRGRXTβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the CorneaPR NewswireROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting that researchers have demonstrated the
- 4y agoRGRXRegeneRx Provides Regulatory Update Regarding RGN-259PR NewswireROCKVILLE, Md., March 2, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information released by HLB Therapeutics
- 4y agoRGRXRegeneRx Consultant to Receive Prestigious Award for Contributions in Field of HealthPR NewswireROCKVILLE, Md., Feb. 11, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, today announced that Dr. Hynda K. Kleinman, a co
- 4y agoRGRXResearchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol InjuryPR NewswireROCKVILLE, Md., Jan. 25, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration), today announced that Chinese researchers confir
- 4y agoRGRXRegeneRx Publishes Regulatory Update on RGN-259PR NewswireROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regar
- 4y agoRGRXRegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022PR NewswireROCKVILLE, Md., Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. FDA has accepted i
- 4y agoRGRXRegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye SyndromePR NewswireROCKVILLE, Md., Nov. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that its U.S. joint venture, ReG
- 5y agoRGRXClinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association MeetingPR NewswireROCKVILLE, Md., Oct. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that the results of the initial
- 5y agoRGRXResearchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with SepsisPR NewswireROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new independent research
- 5y agoRGRXNew Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's DiseasePR NewswireROCKVILLE, Md., Oct. 5, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new research paper was pub
- 5y agoRGRXRegeneRx Licensee Acquired by Korean Biopharmaceutical GroupPR NewswireROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that GtreeBNT, the licensee fo
- 5y agoRGRXRegeneRx Issues Letter To StockholdersPR NewswireROCKVILLE, Md., July 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockhold
- 5y agoABSSFABXXFADDYYAKCCF+44OTC Markets Group Announces Quarterly Index Performance and RebalancingPR NewswireNEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® in
- 5y agoRGRXRegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye SyndromePR NewswireROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture
- 5y agoRGRXRegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private PlacementPR NewswireROCKVILLE, Md., July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it closed its previously an
- 5y agoRGRXRegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private PlacementPR NewswireROCKVILLE, Md., June 28, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it has entered into a defi
- 5y agoRGRXRegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye SyndromePR NewswireROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted a press release from its U.S. joint vent